BST2 induced macrophage M2 polarization to promote the progression of colorectal cancer

被引:33
作者
He, Xuefeng [1 ,5 ]
Chen, Huaijun [6 ]
Zhong, Xinyang [1 ,5 ]
Wang, Yaxian [1 ,5 ]
Hu, Zijuan [2 ,3 ,4 ,5 ]
Huang, Huixia [2 ,3 ,4 ,5 ]
Zhao, Senlin [1 ,5 ]
Wei, Ping [2 ,3 ,4 ,5 ]
Shi, Debing [1 ,5 ]
Li, Dawei [1 ,5 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai 200032, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai, Peoples R China
[4] Fudan Univ, Inst Pathol, Shanghai, Peoples R China
[5] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg, Hangzhou, Peoples R China
基金
美国国家科学基金会;
关键词
BST2; Colorectal cancer (CRC); M2; macrophages; Biomarker; TUMOR-ASSOCIATED MACROPHAGES; MONOCLONAL-ANTIBODY; MULTIPLE-MYELOMA; POOR SURVIVAL; MICROENVIRONMENT; IMMUNOTHERAPY; INSTABILITY; EXPRESSION; ANTIGEN; STATES;
D O I
10.7150/ijbs.72538
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Tumor-associated macrophages (TAMs) are one of the most prominent tumor-infiltrating immune cells in the tumor microenvironment (TME) of CRC and play a vital role in the progression of CRC. BST2 was predicted to be associated with the infiltration of TAMs. However, its potential function by which CRC cells and TAMs interact with each other still needs further investigation. Methods: The target genes in CRC were selected by bioinformatics screening. The level of bone marrow stromal cell antigen 2 (BST2) in CRC cells and tissues was determined by qRT.PCR, Western blotting, and immunohistochemistry staining. In vitro and in vivo assays were applied to clarify the function of BST2. Results: In this study, according to bioinformatics analysis, a nomogram based on the risk score (constructed by BST2 and CAV1 (caveolin-1)) and clinical features was built and displayed satisfactory prognostic value. Upregulated BST2 was significantly related to Braf mutation, dMMR/MSI-H, CMS1 subtype, and immune response and was a potential biomarker for predicting immune checkpoint blockade therapy. Silencing BST2 in CRC obviously restrained CRC progression and M2 TAM polarization. The infiltration of TAMs was positively correlated with the high expression of BST2, and depletion of TAMs alleviated the protumoural effect of BST2 in CRC in vivo. In vitro experiments revealed that a reduction in BST2 in CRC inhibited CRC proliferation and migration and also M2 polarization. Conclusion: These findings indicated that BST2 played a vital role in CRC progression and might be a predictable marker for immunotherapy.
引用
收藏
页码:331 / 346
页数:16
相关论文
共 37 条
[1]   Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010 [J].
Bailey, Christina E. ;
Hu, Chung-Yuan ;
You, Nancy ;
Bednarski, Brian K. ;
Rodriguez-Bigas, Miguel A. ;
Skibber, John M. ;
Cantor, Scott B. ;
Chang, George J. .
JAMA SURGERY, 2015, 150 (01) :17-22
[2]  
Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
[3]   Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis [J].
Cai, Dongqing ;
Cao, Jie ;
Li, Zhen ;
Zheng, Xin ;
Yao, Yao ;
Li, Wanglin ;
Yuan, Ziqiang .
BMC CANCER, 2009, 9
[4]   Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study [J].
Chiang, Sum-Fu ;
Kan, Chih-Yen ;
Hsiao, Yung-Chin ;
Tang, Reiping ;
Hsieh, Ling-Ling ;
Chiang, Jy-Ming ;
Tsai, Wen-Sy ;
Yeh, Chien-Yuh ;
Hsieh, Pao-Shiu ;
Liang, Ying ;
Chen, Jinn-Shiun ;
Yu, Jau-Song .
DISEASE MARKERS, 2015, 2015
[5]   Prognostic Values of EPDR1 Hypermethylation and Its Inhibitory Function on Tumor Invasion in Colorectal Cancer [J].
Chu, Chun-Ho ;
Chang, Shih-Ching ;
Wang, Hsiu-Hua ;
Yang, Shung-Haur ;
Lai, Kuo-Chu ;
Lee, Te-Chang .
CANCERS, 2018, 10 (10)
[6]   Tumor Microenvironment, Metabolism, and Immunotherapy [J].
DeBerardinis, Ralph J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09) :869-871
[7]   Tumor Immunology and Tumor Evolution: Intertwined Histories [J].
Galon, Jerome ;
Bruni, Daniela .
IMMUNITY, 2020, 52 (01) :55-81
[8]   Immunotherapy in colorectal cancer: rationale, challenges and potential [J].
Ganesh, Karuna ;
Stadler, Zsofia K. ;
Cercek, Andrea ;
Mendelsohn, Robin B. ;
Shia, Jinru ;
Segal, Neil H. ;
Diaz, Luis A., Jr. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (06) :361-375
[9]   The consensus molecular subtypes of colorectal cancer [J].
Guinney, Justin ;
Dienstmann, Rodrigo ;
Wang, Xin ;
de Reynies, Aurelien ;
Schlicker, Andreas ;
Soneson, Charlotte ;
Marisa, Laetitia ;
Roepman, Paul ;
Nyamundanda, Gift ;
Angelino, Paolo ;
Bot, Brian M. ;
Morris, Jeffrey S. ;
Simon, Iris M. ;
Gerster, Sarah ;
Fessler, Evelyn ;
Melo, Felipe De Sousa E. ;
Missiaglia, Edoardo ;
Ramay, Hena ;
Barras, David ;
Homicsko, Krisztian ;
Maru, Dipen ;
Manyam, Ganiraju C. ;
Broom, Bradley ;
Boige, Valerie ;
Perez-Villamil, Beatriz ;
Laderas, Ted ;
Salazar, Ramon ;
Gray, Joe W. ;
Hanahan, Douglas ;
Tabernero, Josep ;
Bernards, Rene ;
Friend, Stephen H. ;
Laurent-Puig, Pierre ;
Medema, Jan Paul ;
Sadanandam, Anguraj ;
Wessels, Lodewyk ;
Delorenzi, Mauro ;
Kopetz, Scott ;
Vermeulen, Louis ;
Tejpar, Sabine .
NATURE MEDICINE, 2015, 21 (11) :1350-1356
[10]   Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response [J].
Jiang, Peng ;
Gu, Shengqing ;
Pan, Deng ;
Fu, Jingxin ;
Sahu, Avinash ;
Hu, Xihao ;
Li, Ziyi ;
Traugh, Nicole ;
Bu, Xia ;
Li, Bo ;
Liu, Jun ;
Freeman, Gordon J. ;
Brown, Myles A. ;
Wucherpfennig, Kai W. ;
Liu, X. Shirley .
NATURE MEDICINE, 2018, 24 (10) :1550-+